Aliqopa OverviewCopanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. The FDA awarded copanlisib orphan drug status for follicular lymphoma in February 2015. Phase II clinical trials are in progress for treatment of endometrial cancer, diffuse large B-cell lymphoma, cholangiocarcinoma, and non-Hodgkin lymphoma.[7...
Read more Aliqopa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Copanlisib
Recent Aliqopa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 60mg
- Powder: 60mg/vial
NDC Database Records for Aliqopa: (1 result)Sorted by National Drug Code
- 50419-385 Aliqopa 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Bayer Healthcare Pharmaceuticals Inc.